The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Poly(lactide)–vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Self-citationArtursson, P., & Karlsson, J. (1991) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(91)91647-u · Cited by 1,893
Gelderblom, H., Verweij, J., Nooter, K., & Sparreboom, A. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00171-x · Cited by 1,655
Artursson, P., Palm, K., & Luthman, K. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00128-9 · Cited by 1,543
Yin Win, K., & Feng, S.-S. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2004.07.050 · Cited by 1,452
Self-citationMu, L., & Feng, S. S. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00320-6 · Cited by 725
Self-citationPharmacological Effects of Formulation Vehicles: Implications for Cancer Chemotherapy
ten Tije, A. J., Verweij, J., Loos, W. J., & Sparreboom, A. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342070-00005 · Cited by 591
Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer
Jones, S. E., Erban, J., Overmoyer, B., Budd, G. T., Hutchins, L., Lower, E., Laufman, L., Sundaram, S., Urba, W. J., Pritchard, K. I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.027 · Cited by 547
Zhang, Z., & Feng, S.-S. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2006.03.006 · Cited by 414
Self-citationPoly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs
Dong, Y., & Feng, S.-S. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2005.03.021 · Cited by 395
Self-citationFeng, S.-S., & Chien, S. (2003) · Chemical Engineering Science · doi:10.1016/s0009-2509(03)00234-3 · Cited by 364
Self-citationVarma, M. V. S., & Panchagnula, R. (2005) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.04.003 · Cited by 361
Mu, L., & Feng, S. S. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00025-1 · Cited by 328
Self-citationA study of purified montmorillonite intercalated with 5-fluorouracil as drug carrier
Lin, F. H., Lee, Y. H., Jian, C. H., Wong, J.-M., Shieh, M.-J., & Wang, C.-Y. (2002) · Biomaterials · doi:10.1016/s0142-9612(01)00325-8 · Cited by 298
Oral chemotherapy: rationale and future directions.
DeMario, M. D., & Ratain, M. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2557 · Cited by 293
The effect of physical barriers and properties on the oral absorption of particulates
Norris, D. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00037-4 · Cited by 262
Nanoparticle uptake by the oral route: Fulfilling its potential?
Florence, A. T. (2005) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2005.05.019 · Cited by 248
Zhang, Z., & Feng, S.-S. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2005.05.104 · Cited by 240
Self-citationNanoparticles of biodegradable polymers for new-concept chemotherapy
Feng, S.-S. (2004) · Expert Review of Medical Devices · doi:10.1586/17434440.1.1.115 · Cited by 206
Self-citationCoadministration of Cyclosporine Strongly Enhances the Oral Bioavailability of Docetaxel
Malingré, M. M., Richel, D. J., Beijnen, J. H., Rosing, H., Koopman, F. J., Ten Bokkel Huinink, W. W., Schot, M. E., & Schellens, J. H. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1160 · Cited by 199
Overview of the changing paradigm in cancer treatment: Oral chemotherapy
Aisner, J. (2007) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070035 · Cited by 165
Malingré, M. M., Beijnen, J. H., & Schellens, J. H. M. (2001) · Investigational New Drugs · doi:10.1023/a:1010635000879 · Cited by 158
Plasma pharmacokinetics and tissue distribution of paclitaxel in CD 2 F 1 mice
Eiseman, J. L., Eddington, N. D., Leslie, J. L., MacAuley, C., Sentz, D. L., Zuhowski, M., Kujawa, J. M., Young, D., & Egorin, M. J. (1994) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685656 · Cited by 139
Co-administration of cyclosporin enables oral therapy with paclitaxel
Terwogt, J. M. M., Beijnen, J. H., Huinink, W. W. T. B., Rosing, H., & Schellens, J. H. M. (1998) · The Lancet · doi:10.1016/s0140-6736(98)24030-x · Cited by 129
P-glycoprotein and surfactants: Effect on intestinal talinolol absorption
Bogman, K., Aschmann, Y. Z., DEGEN, L., Gérard Hopfgartner, D., Gutmann, H., Alsenz, J., & Drewe, J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.09.001 · Cited by 126
Zhang, Z., Lee, S. H., Gan, C. W., & Feng, S. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9611-6 · Cited by 122
Self-citationPrasad, Y. V. R., Puthli, S. P., Eaimtrakarn, S., Ishida, M., Yoshikawa, Y., Shibata, N., & Takada, K. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00544-6 · Cited by 122
Phase I and Pharmacokinetic Study of Oral Paclitaxel
Malingré, M. M., Terwogt, J. M. M., Beijnen, J. H., Rosing, H., Koopman, F. J., van Tellingen, O., Duchin, K., Huinink, W. W. T. B., Swart, M., Lieverst, J. A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2468 · Cited by 96
Lee, Y.-H., Kuo, T., Chen, B., et al. (2005) · Biomedical Engineering Applications Basis and Communications · doi:10.4015/s1016237205000111 · Cited by 78
Traber, M. G., Thellman, C., Rindler, M. J., & Kayden, H. (1988) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/48.3.605 · Cited by 63
Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer?
Nabholtz, J., Tonkin, K. S., Smylie, M., Au, H., Lindsay, M.-A., & Mackey, J. R. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.2.187 · Cited by 60
Oral delivery of spray dried PLGA/amifostine nanoparticles
Pamujula, S., Graves, R. A., Freeman, T., Srinivasan, V., Bostanian, L. A., Kishore, V., & Mandal, T. K. (2004) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357044210 · Cited by 47
Lewkowitz-Shpuntoff, H. M., Wen, M. C., Singh, A. K., Brenner, N., Gambino, R. J., Pernodet, N., Isseroff, R., Rafailovich, M. H., & Sokolov, J. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.09.015 · Cited by 39
Fischer, J. R., Harkin, K. R., & Lc, F. (2002) · PubMed · Cited by 34
Malingré, M. M., Beijnen, J. H., Rosing, H., Koopman, F. J., van Tellingen, O., Duchin, K., Huinink, W. W. T. B., Swart, M., Lieverst, J. A., & Schellens, J. H. M. (2001) · Anti-Cancer Drugs · doi:10.1097/00001813-200104000-00008 · Cited by 32
Malingré, M. M., Schellens, J. H. M., van Tellingen, O., Rosing, H., Koopman, F. J., Duchin, K., Huinink, W. W. T. B., Swart, M., & Beijnen, J. H. (2000) · Anti-Cancer Drugs · doi:10.1097/00001813-200011000-00004 · Cited by 28
Biodisponibilité et vecteurs particulaires pour la voie orale
Wawrezinieck, A., Péan, J., Wüthrich, P., & Benoît, J. (2008) · médecine/sciences · doi:10.1051/medsci/20082467659 · Cited by 15
Cited by
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer
Malam, Y., Loizidou, M., & Seifalian, A. M. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.08.004 · Cited by 1,318
Role of nanoparticle size, shape and surface chemistry in oral drug delivery
Banerjee, A., Qi, J., Gogoi, R., Wong, J., & Mitragotri, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.07.051 · Cited by 773
Vitamin E TPGS as a molecular biomaterial for drug delivery
Zhang, Z., Tan, S., & Feng, S.-S. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.03.046 · Cited by 586
Self-citationOral delivery of anticancer drugs: Challenges and opportunities
Thanki, K., Gangwal, R. P., Sangamwar, A. T., & Jain, S. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.020 · Cited by 499
Metadata
- Authors
- Feng, S.-S., Mei, L., Anitha, P., Gan, C. W., & Zhou, W.
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2009-07
- Volume
- 30
- Issue
- 19
- Pages
- 3297-3306
- ISSN
- 0142-9612 (ISSN-L)
- OpenAlex
- W2046605287
- Cited by
- 306
- References
- 37
- FWCI
- 9.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.